Literature DB >> 32219336

miR-210 transferred by lung cancer cell-derived exosomes may act as proangiogenic factor in cancer-associated fibroblasts by modulating JAK2/STAT3 pathway.

Junqiang Fan1, Guanxin Xu1, Zhibo Chang1, Ling Zhu1, Jie Yao1.   

Abstract

It has been generally believed that cancer-associated fibroblasts (CAFs) have the ability to increase the process of tumor angiogenesis. However, the potential mechanisms by which cancer-derived exosomes in lung cancer (LC) remains to be investigated. LC-derived exosomes were administrated to NIH/3T3 cells. A variety of experiments were conducted to investigate the proangiogenic factors of CAFs, including Western blot, RT-PCR, colony formation assay, tube formation assay, Matrigel plug assay et al. In addition, the impact of JAK2/STAT3 signaling pathway were also explored. The role of hsa-miR-210 was identified with microarray profiling and validated in vitro and in vivo assays. The target of miR-210 was screened by RNA pull down, RNA-sequencing and then verified. It was shown that LC-derived exosomes could induce cell reprogramming, thus promoting the fibroblasts transferring into CAFs. In addition, the exosomes with overexpressed miR-210 could increase the level of angiogenesis and vice versa, which suggested the miR-210 secreted by the LC-derived exosomes may initiate the CAF proangiogenic switch. According to our analysis, the miR-210 had the ability of elevating the expression of some proangiogenic factors such as MMP9, FGF2 and vascular endothelial growth factor (VEGF) a (VEGFa) by activating the JAK2/STAT3 signaling pathway, ten-eleven translocation 2 (TET2) was identified as the target of miR-210 in CAFs which has been involved in proangiogenic switch. miR-210 was overexpressed in serum exosomes of untreated non-small cell LC (NSCLC) patients. We concluded that the promotion effect of exosomal miR-210 on proangiogenic switch of CAFs may be explained by the modulation of JAK2/STAT3 signaling pathway and TET2 in recipient fibroblasts.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  Exosomes; JAK2/STAT3 pathway; cancer-associated fibroblasts; lung cancer; miR-210

Year:  2020        PMID: 32219336     DOI: 10.1042/CS20200039

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  33 in total

Review 1.  The role of exosomes in lung cancer metastasis and clinical applications: an updated review.

Authors:  Lei Yin; Xiaotian Liu; Xuejun Shao; Tao Feng; Jun Xu; Qi Wang; Shenghao Hua
Journal:  J Transl Med       Date:  2021-07-19       Impact factor: 5.531

Review 2.  The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives.

Authors:  Zengli Fang; Jin Xu; Bo Zhang; Wei Wang; Jiang Liu; Chen Liang; Jie Hua; Qingcai Meng; Xianjun Yu; Si Shi
Journal:  J Hematol Oncol       Date:  2020-11-19       Impact factor: 17.388

Review 3.  Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy.

Authors:  Jenniffer Linares; Juan A Marín-Jiménez; Jordi Badia-Ramentol; Alexandre Calon
Journal:  Front Cell Dev Biol       Date:  2021-01-22

Review 4.  Noncoding RNAs in the Interplay between Tumor Cells and Cancer-Associated Fibroblasts: Signals to Catch and Targets to Hit.

Authors:  Martina Tassinari; Paolo Gandellini
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

Review 5.  Control of Gene Expression by Exosome-Derived Non-Coding RNAs in Cancer Angiogenesis and Lymphangiogenesis.

Authors:  Valeria Arcucci; Steven A Stacker; Marc G Achen
Journal:  Biomolecules       Date:  2021-02-09

Review 6.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

Review 7.  Exosomes in the lung cancer microenvironment: biological functions and potential use as clinical biomarkers.

Authors:  Runzhi Qi; Yuwei Zhao; Qiujun Guo; Xue Mi; Mengqi Cheng; Wei Hou; Honggang Zheng; Baojin Hua
Journal:  Cancer Cell Int       Date:  2021-06-30       Impact factor: 5.722

Review 8.  Beyond Conventional: The New Horizon of Anti-Angiogenic microRNAs in Non-Small Cell Lung Cancer Therapy.

Authors:  Alexandru Tirpe; Diana Gulei; George Razvan Tirpe; Andreea Nutu; Alexandru Irimie; Paola Campomenosi; Laura Ancuta Pop; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

Review 9.  The Role of Cancer-Associated Fibroblasts and Extracellular Vesicles in Tumorigenesis.

Authors:  Issraa Shoucair; Fernanda Weber Mello; James Jabalee; Saeideh Maleki; Cathie Garnis
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

Review 10.  Circulating MicroRNAs in Blood and Other Body Fluids as Biomarkers for Diagnosis, Prognosis, and Therapy Response in Lung Cancer.

Authors:  Luis Vicente Gayosso-Gómez; Blanca Ortiz-Quintero
Journal:  Diagnostics (Basel)       Date:  2021-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.